104 related articles for article (PubMed ID: 2554766)
21. MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.
Kips JC; Joos GF; De Lepeleire I; Margolskee DJ; Buntinx A; Pauwels RA; Van der Straeten ME
Am Rev Respir Dis; 1991 Sep; 144(3 Pt 1):617-21. PubMed ID: 1892302
[TBL] [Abstract][Full Text] [Related]
22. LY171883, 1-less than 2-hydroxy-3-propyl-4-less than 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist.
Fleisch JH; Rinkema LE; Haisch KD; Swanson-Bean D; Goodson T; Ho PP; Marshall WS
J Pharmacol Exp Ther; 1985 Apr; 233(1):148-57. PubMed ID: 3981452
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir.
Cass LM; Gunawardena KA; Macmahon MM; Bye A
Respir Med; 2000 Feb; 94(2):166-73. PubMed ID: 10714424
[TBL] [Abstract][Full Text] [Related]
24. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma.
Christie PE; Smith CM; Lee TH
Am Rev Respir Dis; 1991 Oct; 144(4):957-8. PubMed ID: 1928974
[TBL] [Abstract][Full Text] [Related]
25. Inhaled epinephrine and oral theophylline-ephedrine in the treatment of asthma.
Pinnas JL; Schachtel BP; Chen TM; Roseberry HR; Thoden WR
J Clin Pharmacol; 1991 Mar; 31(3):243-7. PubMed ID: 2019665
[TBL] [Abstract][Full Text] [Related]
26. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.
De Lepeleire I; Reiss TF; Rochette F; Botto A; Zhang J; Kundu S; Decramer M
Clin Pharmacol Ther; 1997 Jan; 61(1):83-92. PubMed ID: 9024176
[TBL] [Abstract][Full Text] [Related]
27. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma.
Wasserman SI; Gross GN; Schoenwetter WF; Munk ZM; Kral KM; Schaberg A; Kellerman DJ
J Asthma; 1996; 33(4):265-74. PubMed ID: 8707781
[TBL] [Abstract][Full Text] [Related]
28. Fluticasone propionate compared with theophylline for mild-to-moderate asthma.
Galant SP; Lawrence M; Meltzer EO; Tomasko M; Baker KA; Kellerman DJ
Ann Allergy Asthma Immunol; 1996 Aug; 77(2):112-8. PubMed ID: 8760776
[TBL] [Abstract][Full Text] [Related]
29. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
Leff JA; Busse WW; Pearlman D; Bronsky EA; Kemp J; Hendeles L; Dockhorn R; Kundu S; Zhang J; Seidenberg BC; Reiss TF
N Engl J Med; 1998 Jul; 339(3):147-52. PubMed ID: 9664090
[TBL] [Abstract][Full Text] [Related]
30. Metaproterenol sulfate for asthmatic children with therapeutic serum theophylline concentrations.
Kelly HW; Menendez R; Murphy S; Tuttle W
Clin Pharm; 1982; 1(1):49-54. PubMed ID: 6764162
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the safety and efficacy of multiple doses of azelastine to adult patients with bronchial asthma over time.
Tinkelman DG; Bucholtz GA; Kemp JP; Koepke JW; Repsher LH; Spector SL; Storms WW; Van As A
Am Rev Respir Dis; 1990 Mar; 141(3):569-74. PubMed ID: 2178521
[TBL] [Abstract][Full Text] [Related]
32. Metaproterenol in children with chronic asthma.
Hyde JS; Yamshon D; Isenberg PD; Schur S
Clin Pharmacol Ther; 1976 Aug; 20(2):207-12. PubMed ID: 780039
[TBL] [Abstract][Full Text] [Related]
33. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group.
Laviolette M; Malmstrom K; Lu S; Chervinsky P; Pujet JC; Peszek I; Zhang J; Reiss TF
Am J Respir Crit Care Med; 1999 Dec; 160(6):1862-8. PubMed ID: 10588598
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing.
Kerwin EM; Oppenheimer JJ; LaForce C; Parasuraman B; Miller CJ; O'Dowd L; Goldman M
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):62-72. PubMed ID: 19663129
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy.
Chodosh S; Crooks LA; Tuck J
J Asthma; 1989; 26(5):309-15. PubMed ID: 2484663
[TBL] [Abstract][Full Text] [Related]
36. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group.
van Essen-Zandvliet EE; Hughes MD; Waalkens HJ; Duiverman EJ; Pocock SJ; Kerrebijn KF
Am Rev Respir Dis; 1992 Sep; 146(3):547-54. PubMed ID: 1355640
[TBL] [Abstract][Full Text] [Related]
37. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
38. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
Busse WW; Casale TB; Murray JJ; Petrocella V; Cox F; Rickard K
Am J Manag Care; 1998 Nov; 4(11):1579-87. PubMed ID: 10338904
[TBL] [Abstract][Full Text] [Related]
40. Indomethacin and LY171883 modify porcine cardiopulmonary responses to leukotrienes.
Olson NC; Fleisher LN
Prostaglandins Leukot Essent Fatty Acids; 1989 Mar; 35(3):175-82. PubMed ID: 2496411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
